Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community

Rhea-AI Summary

Horizon Therapeutics plc (Nasdaq: HZNP) has launched the #RAREis Global Advocate Grant, aimed at supporting patient advocacy groups in the rare disease community. This initiative will provide financial assistance of $5,000 to up to 30 qualifying organizations in 2022. Applications are open from May 2 to June 3, with the recipients announced in June and funds disbursed in July. The program reflects Horizon's commitment to addressing the needs of the rare disease community.

Positive

• Launch of #RAREis Global Advocate Grant to support patient advocacy groups.
• Financial assistance of $5,000 available for up to 30 organizations.
• Demonstrates commitment to the rare disease community and innovation.

Negative

• None.

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the #RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance to U.S. and global patient advocacy groups working to advance, educate and address the needs of the community.

With more than 7,000 known rare diseases impacting over 400 million people worldwide, the need for rare disease innovation is significant. The #RAREis Global Advocate Grant is committed to making a positive difference for the rare disease community.

In 2022, up to 30 patient advocacy groups will be eligible to receive a one-time $5,000 grant. In order to qualify, groups will be required to submit a request. Horizon will manage the application process, selection and distribution of the grants. Applications will be evaluated based on the needs outlined by each patient advocacy organization that applies, as well as the potential impact of the grant. For more information and to apply, visit RAREiscommunity.com/Grant. Applications are open from Monday, May 2 to Friday, June 3, 2022. Recipients will be announced in June and grants will be provided in July 2022.

“Horizon’s approach is to listen, learn and understand the challenges of the rare disease community, ultimately working to help patients get better educated, engage with each other and seek the best possible care,” said Matt Flesch, vice president, communications and patient advocacy, Horizon. “Finding new ways to support the community is the driving force behind what we do each day, and the #RAREis Global Advocate Grant will help many smaller rare non-profit organizations better educate and engage their communities.”

The #RAREis Global Advocate Grant is the latest expansion of Horizon’s #RAREis™ program, which is committed to improving the experience of living with a rare disease, by providing support to many organizations that offer crucial programs and services for people living with rare diseases. Other #RAREis programs include the #RAREis Playlist, #RAREis Adoption Fund, and #RAREis Scholarship.

About #RAREis

In February of 2017, Horizon launched the #RAREis program aimed at elevating the voices, faces and experiences of people living with rare diseases, as well as highlight programs and resources for the rare disease community. The program is anchored by an Instagram page and website that showcases photos and stories of people touched by rare disease and captures elements of their patient, caregiver or advocate experience. To learn more, visit the #RAREis Instagram and Facebook page and visit the website at www.RAREisCommunity.com.

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005133/en/

U.S. Media Contacts:

Michelle Rivas

Sr. Manager, Product Communications

media@horizontherapeutics.com



Ireland Media Contact:

Gordon MRM

Ray Gordon

ray@gordonmrm.ie

Source: Horizon Therapeutics plc

FAQ

What is the purpose of the #RAREis Global Advocate Grant launched by HZNP?

The #RAREis Global Advocate Grant aims to support patient advocacy groups in the rare disease community by providing financial assistance.

How much financial assistance is available through the #RAREis Global Advocate Grant?

Up to $5,000 will be awarded to each of the up to 30 selected patient advocacy groups.

When can organizations apply for the #RAREis Global Advocate Grant?

Applications are open from May 2 to June 3, 2022.

When will the recipients of the #RAREis Global Advocate Grant be announced?

Recipients will be announced in June 2022.

When will the grants from the #RAREis Global Advocate Grant be distributed?

Grants will be provided in July 2022.